State Street Corp boosted its stake in shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) by 14.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 671,388 shares of the medical device company’s stock after buying an additional 83,602 shares during the period. State Street Corp owned about 2.05% of Cardiovascular Systems worth $18,982,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of CSII. Quantbot Technologies LP raised its position in Cardiovascular Systems by 142.3% in the first quarter. Quantbot Technologies LP now owns 5,323 shares of the medical device company’s stock valued at $150,000 after buying an additional 3,126 shares during the last quarter. Winslow Evans & Crocker Inc. acquired a new position in Cardiovascular Systems during the first quarter valued at about $153,000. Old Mutual Global Investors UK Ltd. acquired a new position in Cardiovascular Systems during the first quarter valued at about $163,000. Clinton Group Inc. acquired a new position in Cardiovascular Systems during the first quarter valued at about $212,000. Finally, Koch Industries Inc. acquired a new position in Cardiovascular Systems during the first quarter valued at about $229,000. 74.82% of the stock is currently owned by institutional investors and hedge funds.

Cardiovascular Systems, Inc. (NASDAQ:CSII) traded up 0.19% during trading on Tuesday, hitting $30.90. 13,314 shares of the stock traded hands. Cardiovascular Systems, Inc. has a 12 month low of $21.29 and a 12 month high of $33.11. The firm’s market cap is $1.01 billion. The firm has a 50-day moving average price of $31.68 and a 200 day moving average price of $29.68.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.07. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.89%. The firm had revenue of $52.90 million for the quarter, compared to the consensus estimate of $51.98 million. During the same period last year, the firm earned ($0.15) earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. On average, equities analysts forecast that Cardiovascular Systems, Inc. will post $0.04 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “State Street Corp Boosts Position in Cardiovascular Systems, Inc. (CSII)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/15/state-street-corp-boosts-position-in-cardiovascular-systems-inc-csii.html.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, August 4th. TheStreet upgraded shares of Cardiovascular Systems from a “d” rating to a “c-” rating in a report on Thursday, May 4th. BidaskClub lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Bank of America Corporation lowered shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Cardiovascular Systems in a report on Tuesday, April 18th. Three research analysts have rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $33.83.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSII).

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.